Who is sponsoring NCT03916913?

NCT03916913 is sponsored by Chinese Academy of Medical Sciences.

What drugs are being tested in NCT03916913?

Interventions in NCT03916913: Local radiation therapy.

What condition does NCT03916913 study?

NCT03916913 studies Non-Small Cell Lung Cancer Metastatic.

Is NCT03916913 still recruiting?

NCT03916913 is currently status unknown. Last updated 17 April 2019.

Last reviewed 2019-04-17 · How we verify

NCT03916913

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

Status unknown NA Last updated 17 April 2019

What this trial tests

NA trial testing Local radiation therapy in Non-Small Cell Lung Cancer Metastatic in 85 participants. Status unknown.

Timeline

1 January 2019

Primary endpoint
1 January 2022

1 January 2023

Quick facts

Lead sponsor	Chinese Academy of Medical Sciences
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	85
Start date	1 January 2019
Primary completion	1 January 2022
Estimated completion	1 January 2023
Sites	1 location across China

Drugs / interventions tested

Local radiation therapy

Conditions studied

Non-Small Cell Lung Cancer Metastatic — all drugs for Non-Small Cell Lung Cancer Metastatic →

Sponsor

Chinese Academy of Medical Sciences — full company profile →

Who can join

Adults 18 to 75, any sex, with Non-Small Cell Lung Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this phase II trial with single arm, we aim to investigate the clinical efficacy and toxicity profile of local radiotherapy on all disease sites for EGFR-mutant oligo-metastatic NSCLC (no more than 3 metastatic lesions) who did not experience disease progression after at least 3 months of TKI therapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?
Liu B, Liu H, Ma Y, Ding Q, et al · · 2021 · cited 11× · PMID 34374490 · DOI 10.1002/cam4.4192
Current and future research efforts in oligometastatic non-small cell lung cancer-a systematic review.
Brandão M, Durieux V, Berghmans T. · · 2021 · cited 4× · PMID 34430381 · DOI 10.21037/tlcr-20-964

Verify or expand the search:

Other recruiting trials for Non-Small Cell Lung Cancer Metastatic

Currently open trials in the same condition.

NCT07144280 — A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ · Phase 3 · recruiting
NCT06106802 — Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment · Phase 2 · recruiting
NCT04619004 — HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung · Phase 2 · active not recruiting

Other Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03916913 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
Last refreshed: 17 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03916913.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing